ConductScience.org, home

Paper26789727

Assessment of Minimal Residual Disease in Standard-Risk AML.

Ivey A and 22 others. N Engl J Med, 2016. Cited by 704 papers, by iCite.

Cite this record

ConductScience Library. Assessment of Minimal Residual Disease in Standard-Risk AML. Papers, record 26789727. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26789727

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Assessment of Minimal Residual Disease in Standard-Risk AML.
PubMed
Journal
N Engl J Med
PubMed
Year
2016
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
704
iCite
Relative citation ratio, by iCite
21.9
iCite
Revised in PubMed
2025-05-29
PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ivey AAdam
2Hills RKRobert K
3Simpson MAMichael A
4Jovanovic JVJelena V
5Gilkes AAmanda
6Grech AAngela
7Patel YYashma
8Bhudia NNeesa
9Farah HHassan
10Mason JJoanne
11Wall KKerry
12Akiki SSusanna
13Griffiths MMichael
14Solomon EEllen
15McCaughan FFrank
16Linch DCDavid C
17Gale RERosemary E
18Vyas PParesh
19Freeman SDSylvie D
20Russell NNigel

Source PubMed

See all 23 authorsDownload CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia, Myeloid, AcuteMajor topic
MutationMajor topic
Nuclear ProteinsMajor topic
Base Sequence
DNA, Neoplasm
Exome
Gene Expression Profiling
Humans
Molecular Sequence Data
Neoplasm, Residual
Nucleophosmin
Prognosis
Recurrence
Reverse Transcriptase Polymerase Chain Reaction
Risk Factors
Transcriptome

Source PubMed

Download CSV of topics

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
RP-PG-0108-10093Department of HealthUnited KingdomPubMed
9948Cancer Research UKUnited KingdomPubMed
G0500392Medical Research CouncilUnited KingdomPubMed
15556Cancer Research UKUnited KingdomPubMed
G1000729Medical Research CouncilUnited KingdomPubMed
WT097143MAWellcome TrustUnited KingdomPubMed
MR/L008963/1Medical Research CouncilUnited KingdomPubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04689815Oral Arsenic Trioxide for NPM1-mutated AMLBackground

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections6

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in26789634Minimal Residual Disease in NPM1-Mutated AML.https://conductscience.org/library/papers/26789634PubMed
Comment in26856743Haematological cancer: MRD assessment - guiding decisions for patients with AML.https://conductscience.org/library/papers/26856743PubMed
Comment in27509124Assessment of Minimal Residual Disease in Standard-Risk AML.https://conductscience.org/library/papers/27509124PubMed
Comment in27509125Assessment of Minimal Residual Disease in Standard-Risk AML.https://conductscience.org/library/papers/27509125PubMed
Comment in27509126Assessment of Minimal Residual Disease in Standard-Risk AML.https://conductscience.org/library/papers/27509126PubMed
Comment in27509127Assessment of Minimal Residual Disease in Standard-Risk AML.https://conductscience.org/library/papers/27509127PubMed

Download CSV of comments and corrections

Cited by459

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 704 citations.

PMIDTitleJournalYearIn PapersSource
42946711Outcomes with fractionated gemtuzumab ozogamicin in molecularly defined favorable-risk acute myeloid leukemia.Blood Cancer J2026https://conductscience.org/library/papers/42946711PubMed
42938803Interferon Therapy in Acute Myeloid Leukemia: Biological Rationale, Clinical Evidence, and Future Directions.Cancers (Basel)2026https://conductscience.org/library/papers/42938803PubMed
42850349Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy.Leukemia2026https://conductscience.org/library/papers/42850349PubMed
42795012Two Decades of NPM1-Mutated Acute Myeloid Leukemia: From Molecular Insights to Clinical Decision-Making.Cancers (Basel)2026https://conductscience.org/library/papers/42795012PubMed
42739525Indications for Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation in Adults: State of the Art.J Clin Med2026https://conductscience.org/library/papers/42739525PubMed
42649900FLT3-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for FLT3 Inhibitor-Based Therapies.Cancers (Basel)2026https://conductscience.org/library/papers/42649900PubMed
42640163Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.NEJM Evid2026https://conductscience.org/library/papers/42640163PubMed
42599754FLT3-ITD MRD is here to stay.Blood Adv2026https://conductscience.org/library/papers/42599754PubMed
42545548Analytical validation of a modified wild-type blocker qpcr assay for the sensitive DNA-based detection of NPM1 type A in acute myeloid leukemia.Mol Biol Rep2026https://conductscience.org/library/papers/42545548PubMed
42532509Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML.Blood Adv2026https://conductscience.org/library/papers/42532509PubMed
42471330Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms.Blood Cancer J2026https://conductscience.org/library/papers/42471330PubMed
42469476Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.Leukemia2026https://conductscience.org/library/papers/42469476PubMed
42452347Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin.J Clin Med2026https://conductscience.org/library/papers/42452347PubMed
42439986MRD-driven HDACi-based therapy post-transplant: a real-world study in high-risk acute myeloid leukemia.Ann Hematol2026https://conductscience.org/library/papers/42439986PubMed
42350077When MRD Is Not MRD: A Context-Dependent Interpretation in Clinical Decision-Making.Eur J Haematol2026https://conductscience.org/library/papers/42350077PubMed
42329370[Guideline development for MRD diagnostics in AML as a blueprint for solid tumors].Pathologie (Heidelb)2026https://conductscience.org/library/papers/42329370PubMed
42279386Advances in Immune Checkpoint Inhibitors for Cancer Treatment.Cancers (Basel)2026https://conductscience.org/library/papers/42279386PubMed
42249961Splicing factor mutations clearance and outcomes in clonal myeloid neoplasms: a referral center experience.Ann Hematol2026https://conductscience.org/library/papers/42249961PubMed
42230972
Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.
Br J Haematol2026https://conductscience.org/library/papers/42230972PubMed
42196346Early Peripheral Blood WT1 Expression Predicts Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.Int J Mol Sci2026https://conductscience.org/library/papers/42196346PubMed

See all 459 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
NPM14869PubTator's text mininghttps://conductscience.org/library/genes/4869

Source NCBI Gene

Download CSV of genes

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
ISRCTNISRCTN55675535

Source ISRCTN

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • References
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26789727

GET https://conductscience.org/api/papers/v1/26789727/authors?page=2